09:13 AM EST, 11/11/2024 (MT Newswires) -- Ainos (AIMD) said Monday it has received approval from the Institutional Review Board of Shuang Ho Hospital in Taiwan for the conduct of a clinical study of Veldona to treat Sjogren's syndrome.

The company said it intends to submit to Taiwan's Food and Drug Administration by the end of this year and expects to receive all regulatory approvals in Q1 next year as well as conduct a site initiation visit around April.

The study aims to evaluate Veldona's efficacy in improving salivary flow and reducing dryness symptoms in patients with Sjogren's syndrome, Ainos said, adding it expects to enroll 24 participants for a 24- to 48-week treatment period.

Shares of the company were down 2.2% in recent Monday premarket activity.